The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.

The sizable yield comes with a concerning footnote. Just look at the rest of the story.

Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b pharmaceutical group is positioned, with value metrics and recent returns drawing ...

Pfizer (NYSE:PFE) has announced a new CFO transition as Dave Denton prepares to step down in August, adding another management change at a time when the drugmaker is still working to rebuild growth ...

Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.

Pfizer PFE is one of the world’s leading oncology drugmakers, with a strong presence across breast, genitourinary, thoracic, ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

Pfizer (NYSE: PFE) shares gained 2.8% through 11:15 a.m. ET Thursday, and investors can thank the friendly bankers at RBC Capital Markets for that. This morning, RBC removed its sell rating from ...

Income investors watching the calendar have a narrow window this week. Three of the market’s most widely held high-yield ...

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

It's entirely possible that Pfizer stock will indeed rebound this year. Perhaps the most likely reason for a bounce is the potential for positive clinical results that excite investors. Many will ...

Pfizer (PFE) stock, Alnylam (ALNY) stock and BridgeBio (BBIO) stock jump after a trial setback for an ATTE-CM drug from Astra ...